Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS‐CoV‐2: Possible molecular mechanisms

Abstract

AbstractPurposeThe SARS‐CoV‐2 pandemic prompted the development and use of next‐generation vaccines. Among these, mRNA‐based vaccines consist of injectable solutions of mRNA encoding for a recombinant Spike, which is distinguishable from the wild‐type protein due to specific amino acid variations introduced to maintain the protein in a prefused state. This work presents a proteomic approach to reveal the presence of recombinant Spike protein in vaccinated subjects regardless of antibody titer.Experimental designMass spectrometry examination of biological samples was used to detect the presence of specific fragments of recombinant Spike protein in subjects who received mRNA‐based vaccines.ResultsThe specific PP‐Spike fragment was found in 50% of the biological samples analyzed, and its presence was independent of the SARS‐CoV‐2 IgG antibody titer. The minimum and maximum time at which PP‐Spike was detected after vaccination was 69 and 187 days, respectively.Conclusions and clinical relevanceThe presented method allows to evaluate the half‐life of the Spike protein molecule “PP” and to consider the risks or benefits in continuing to administer additional booster doses of the SARS‐CoV‐2 mRNA vaccine. This approach is of valuable support to complement antibody level monitoring and represents the first proteomic detection of recombinant Spike in vaccinated subjects.